• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2023 06

21

TYK Medicine TYK-00540—The first CDK2/4/6 inhibitor in China approved by FDA to conduct clinical trial

Discover More
2023 05

29

TYK Medicines and WuXi STA Launch Comprehensive Strategic Cooperation

Discover More
2023 05

17

TYK Medicine TY-2699a —The CDK7 inhibitorapproved by CDE to conduct clinical trial

Discover More
2023 04

28

TYK Medicines receives CDE Conditional Market Authorization for TY-9591

Discover More
2023 04

07

TYK Medicines TY-4028 —The EGFR/HER2 tyrosine kinase inhibitor approved by FDA to conduct the clinical trial

Discover More
2023 04

04

TYK Medicines will present the research progress and results of 6 innovative drug projects at the 2023 Annual Meeting of American Association for Cancer Research (AACR 2023)

Discover More
<12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号